The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options
Abstract
The increasing prevalence of infections due to multidrug-resistant (MDR) gram-negative bacteria constitutes a serious threat to global public health due to the limited treatment options available and the historically slow pace of development of new antimicrobial agents. Infections due to MDR strains are associated with increased morbidity and mortality and prolonged hospitalization, which translates to a significant burden on healthcare systems. In particular, MDR strains of Enterobacteriaceae (especially Klebsiella pneumoniae and Escherichia coli), Pseudomonas aeruginosa, and Acinetobacter baumannii have emerged as particularly serious concerns. In the United States, MDR strains of these organisms have been reported from hospitals throughout the country and are not limited to a small subset of hospitals. Factors that have contributed to the persistence and spread of MDR gram-negative bacteria include the following: overuse of existing antimicrobial agents, which has led to the development of adaptive resistance mechanisms by bacteria; a lack of good antimicrobial stewardship such that use of multiple broad-spectrum agents has helped perpetuate the cycle of increasing resistance; and a lack of good infection control practices. The rising prevalence of infections due to MDR gram-negative bacteria presents a significant dilemma in selecting empiric antimicrobial therapy in seriously ill hospitalized patients. A prudent initial strategy is to initiate treatment with a broad-spectrum regimen pending the availability of microbiological results allowing for targeted or narrowing of therapy. Empiric therapy with newer agents that exhibit good activity against MDR gram-negative bacterial strains such as tigecycline, ceftolozane-tazobactam, ceftazidime-avibactam, and others in the development pipeline offer promising alternatives to existing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Multistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Mermel, L. A., Allon, M., Bouza, E., Craven, D. E., Flynn, P., O'Grady, N. P., Raad, I. I., Rijnders, B. J. A., Sherertz, R. J., & Warren, D. K. (2009) · Clinical Infectious Diseases · doi:10.1086/599376 · Cited by 3,638
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Ambler, R. P. (1980) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1980.0049 · Cited by 1,823
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Molecular Mechanisms of Antibacterial Multidrug Resistance
Alekshun, M. N., & Levy, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.03.004 · Cited by 1,647
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., Fridkin, S., & National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/668770 · Cited by 1,582
Pseudomonas aeruginosa: all roads lead to resistance
Breidenstein, E. B. M., de la Fuente-Núñez, C., & Hancock, R. E. W. (2011) · Trends in Microbiology · doi:10.1016/j.tim.2011.04.005 · Cited by 1,286
Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., Gencay, M. M., Huber, P. R., Tamm, M., & Müller, B. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15591-8 · Cited by 1,096
Tumbarello, M., Viale, P., Viscoli, C., Trecarichi, E. M., Tumietto, F., Marchese, A., Spanu, T., Ambretti, S., Ginocchio, F., Cristini, F., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis588 · Cited by 1,016
Emergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Epidemiology and Outcomes of Health-care–Associated Pneumonia
Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. S. (2005) · Chest · doi:10.1378/chest.128.6.3854 · Cited by 948
Adaptive and Mutational Resistance: Role of Porins and Efflux Pumps in Drug Resistance
Fernández, L., & Hancock, R. E. W. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00043-12 · Cited by 892
Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia: A Randomized Trial
Christ-Crain, M., Stolz, D., Bingisser, R., Müller, C., Miedinger, D., Huber, P. R., Zimmerli, W., Harbarth, S., Tamm, M., & Müller, B. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1922oc · Cited by 884
Tacconelli, E., Cataldo, M. A., Dancer, S. J., De Angelis, G., Falcone, M., Frank, U., Kahlmeter, G., Pan, A., Petrosillo, N., Rodríguez-Baño, J., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12427 · Cited by 864
Snitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Lautenbach, E., Patel, J. B., Bilker, W. B., Edelstein, P. H., & Fishman, N. O. (2001) · Clinical Infectious Diseases · doi:10.1086/319757 · Cited by 747
Jones, R. N. (2010) · Clinical Infectious Diseases · doi:10.1086/653053 · Cited by 716
Alvarez-Lerma, F., & ICU-Acquired Pneumonia Study Group (1996) · Intensive Care Medicine · doi:10.1007/bf01712153 · Cited by 652
Bacterial Resistance: Origins, Epidemiology, and Impact
Livermore, D. M. (2003) · Clinical Infectious Diseases · doi:10.1086/344654 · Cited by 586
Cai, Y., Chai, D., Wang, R., Liang, B., & Bai, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks084 · Cited by 557
Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections
Solomkin, J. S., Mazuski, J. E., Baron, E. J., Sawyer, R. G., Nathens, A. B., DiPiro, J. T., Buchman, T., Dellinger, E. P., Jernigan, J., Gorbach, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/378702 · Cited by 515
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter
Livermore, D. M., & Woodford, N. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.07.008 · Cited by 510
Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens
Pfeifer, Y., Cullik, A., & Witte, W. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.005 · Cited by 494
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
RELLO, J., GALLEGO, M., MARISCAL, D., SOÑORA, R., & VALLES, J. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.1.9607030 · Cited by 467
Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing
Lim, L. M., Ly, N., Anderson, D., Yang, J. C., Macander, L., Jarkowski, A., Forrest, A., Bulitta, J. B., & Tsuji, B. T. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.12.1279 · Cited by 444
Lledo, W., Hernández, M., Lopez, E., Molinari, O. L., Soto, R. Q., Hernández, E., Vispo, N. S., Flores, M., Vázquez, G. J., Robledo, I. E., et al. (2009) · PubMed · Cited by 430
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Mauldin, P. D., Salgado, C. D., Hansen, I. S., Durup, D. T., & Bosso, J. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01041-09 · Cited by 360
Zhanel, G. G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Walkty, A., et al. (2014) · Drugs · doi:10.1007/s40265-013-0168-2 · Cited by 340
Clinical and economic burden of antimicrobial resistance
Maragakis, L. L., Perencevich, E. N., & Cosgrove, S. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.751 · Cited by 329
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 312
Doi, Y., Park, Y. S., Rivera, J. I., Adams-Haduch, J. M., Hingwe, A., Sordillo, E. M., Lewis, J. S., Howard, W. J., Johnson, L. E., Polsky, B., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis942 · Cited by 303
Resistance to polymyxins: Mechanisms, frequency and treatment options
Falagas, M. E., Rafailidis, P. I., & Matthaiou, D. K. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.05.002 · Cited by 298
Multidrug-Resistant Gram-Negative Infections: What are the Treatment Options?
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 288
Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1
Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.972-978.2003 · Cited by 286
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Kanj, S. S., & Kanafani, Z. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0674 · Cited by 269
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., & Woodford, N. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00756-10 · Cited by 261
Cabot, G., Bruchmann, S., Mulet, X., Zamorano, L., Moyà, B., Juan, C., Haussler, S., & Oliver, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02462-13 · Cited by 247
Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01288-13 · Cited by 235
Lucasti, C., Popescu, I., Ramesh, M. K., Lipka, J., & Sable, C. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks523 · Cited by 234
Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., & Docquier, J.-D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02247-12 · Cited by 230
Shorr, A. F., Zilberberg, M. D., Micek, S. T., & Kollef, M. H. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.20.2205 · Cited by 226
Vazquez, J. A., González Patzán, L. D., Stricklin, D., Duttaroy, D. D., Kreidly, Z., Lipka, J., & Sable, C. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.748653 · Cited by 219
Gagliotti, C., Balode, A., Baquero, F., Degener, J., Grundmann, H., Gür, D., Jarlier, V, Kahlmeter, G., Monen, J., Monnet, D. L., et al. (2011) · Eurosurveillance · doi:10.2807/ese.16.11.19819-en · Cited by 203
Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
Zhanel, G. G., Lawson, C. D., Zelenitsky, S., Findlay, B., Schweizer, F., Adam, H., Walkty, A., Rubinstein, E., Gin, A. S., Hoban, D. J., et al. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.25 · Cited by 201
Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M., & Quale, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm129 · Cited by 192
Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01896-13 · Cited by 177
Aktaş, Z., Kayacan, C., & Oncul, O. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.09.012 · Cited by 169
Lagacé-Wiens, P., Walkty, A., & Karlowsky, J. (2014) · Core Evidence · doi:10.2147/ce.s40698 · Cited by 169
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Blizzard, T. A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., Imbriglio, J., Young, K., Park, Y.-W., Ogawa, A., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.101 · Cited by 168
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Hsueh, P., Hoban, D. J., Carmeli, Y., Chen, S., Desikan, S., Alejandria, M., Ko, W., & Bình, T. Q. (2011) · Journal of Infection · doi:10.1016/j.jinf.2011.05.015 · Cited by 149
Sader, H. S., Farrell, D. J., Castanheira, M., Flamm, R. K., & Jones, R. N. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku184 · Cited by 149
Farrell, D. J., Sader, H. S., Flamm, R. K., & Jones, R. N. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.032 · Cited by 146
Hirsch, E. B., Ledesma, K. R., Chang, K., Schwartz, M. S., Motyl, M. R., & Tam, V. H. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05927-11 · Cited by 145
Abdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Landman, D., & Quale, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04809-14 · Cited by 144
Levison, M. E., & Kaye, D. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0315-7 · Cited by 132
Stein, G. E. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)86734-x · Cited by 131
Cost of Gram-negative resistance*
Evans, H. L., Lefrak, S. N., Lyman, J. A., Smith, R. L., Chong, T. W., McElearney, S. T., Schulman, A. R., Hughes, M. G., Raymond, D. P., Pruett, T. L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000251496.61520.75 · Cited by 128
Combating multidrug-resistant Gram-negative bacterial infections
Xu, Z., Flavin, M. T., & Flavin, J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.848853 · Cited by 126
Economics of antibiotic resistance
Sıpahı, O. R. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.4.523 · Cited by 125
Klebsiella pneumoniaeAntimicrobial Drug Resistance, United States, 1998–2010
Sanchez, G. V., Master, R. N., Clark, R. B., Fyyaz, M., Duvvuri, P. D., Ekta, G., & Bordón, J. (2012) · Emerging infectious diseases · doi:10.3201/eid1901.120310 · Cited by 125
Canadian Guidelines for the Management of Acute Exacerbations of Chronic Bronchitis
Balter, M. S., Forge, J. L., Low, D. E., Mandell, L. A., Grossman, R. F., & the Chronic Bronchitis Working Group (2003) · Canadian Respiratory Journal · doi:10.1155/2003/486285 · Cited by 125
Management of Urinary Tract Infections From Multidrug-Resistant Organisms
Gupta, K., & Bhadelia, N. (2013) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2013.10.002 · Cited by 123
Polymyxin B hemoperfusion: a mechanistic perspective
Ronco, C., & Klein, D. J. (2014) · Critical Care · doi:10.1186/cc13912 · Cited by 121
Solomkin, J. S., Ramesh, M. K., Česnauskas, G., Novikovs, N., Stefanova, P. P., Sutcliffe, J. A., Walpole, S. M., & Horn, P. T. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01614-13 · Cited by 120
Complicated urinary tract infections
Lichtenberger, P., & Hooton, T. M. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0081-0 · Cited by 119
Maruyama, T., Fujisawa, T., Okuno, M., Toyoshima, H., Tsutsui, K., Maeda, H., Yuda, H., Yoshida, M., Kobayashi, H., Taguchi, O., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit571 · Cited by 119
Miller, D. L., & O’Grady, N. P. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.04.023 · Cited by 118
Emerging Resistant Gram-Negative Aerobic Bacilli in Hospital-Acquired Infections
Kunz, A. N., & Brook, I. (2010) · Chemotherapy · doi:10.1159/000321018 · Cited by 117
Connors, K. P., Housman, S. T., Pope, J. S., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02036-13 · Cited by 117
Walkty, A. J., Adam, H. J., Baxter, M. R., Denisuik, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 116
Klein, D. J., Foster, D., Schorr, C., Kazempour, K., Walker, P. M., & Dellinger, R. P. (2014) · Trials · doi:10.1186/1745-6215-15-218 · Cited by 115
LUCASTI, C. J., Hershberger, E., Miller, B. W., Yankelev, S., Steenbergen, J. N., Friedland, I. R., & Solomkin, J. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00049-14 · Cited by 114
Sligl, W., Taylor, G. D., & Brindley, P. G. (2006) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2005.07.003 · Cited by 112
The Emerging Threat of Multidrug-Resistant Gram-Negative Organisms in Long-Term Care Facilities
O’Fallon, E., Pop-Vicas, A. E., & D’Agata, E. M. C. (2009) · The Journals of Gerontology Series A · doi:10.1093/gerona/gln020 · Cited by 108
Vasilev, K. A., Reshedko, G., Orăsan, R., Sánchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn249 · Cited by 102
Cardoso, T., Ribeiro, O., Aragão, I. C., Costa‐Pereira, A., & Sarmento, A. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-375 · Cited by 102
Kollef, M. H., Golan, Y., Micek, S. T., Shorr, A. F., & Restrepo, M. I. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir475 · Cited by 101
Zilberberg, M. D., & Shorr, A. F. (2013) · Journal of Hospital Medicine · doi:10.1002/jhm.2080 · Cited by 97
Skin and soft-tissue infections: Classifying and treating a spectrum
Rajan, S. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.11044 · Cited by 95
Gardiner, D., Dukart, G., Cooper, A., & Babinchak, T. (2009) · Clinical Infectious Diseases · doi:10.1086/648720 · Cited by 91
McKinnell, J. A., Stollenwerk, N. S., Jung, C. W., & Miller, L. G. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0800 · Cited by 89
Trends in antimicrobial resistance in intensive care units in the United States
Prabaker, K. K., & Weinstein, R. A. (2011) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32834a4b03 · Cited by 88
Eckmann, C., Montravers, P., Bassetti, M., Bodmann, K. ‐., Heizmann, W. R., García, M. S., Guirao, X., Capparella, M. R., Simoneau, D., & Dupont, H. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt142 · Cited by 84
Micek, S. T., Welch, E. C., Khan, J., Pervez, M., Doherty, J. A., Reichley, R. M., Hoppe‐Bauer, J., Dunne, W. M., & Kollef, M. H. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.899 · Cited by 83
Early Management of Severe Sepsis
Marik, P. E. (2014) · CHEST Journal · doi:10.1378/chest.13-2104 · Cited by 79
Pharmacokinetic and pharmacodynamic evaluation of tigecycline
Giamarellou, H., & Poulakou, G. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.623126 · Cited by 78
Dubois, V., Arpin, C., Melon, M., Melon, B., Andre, C., Frigo, C., & Quentin, C. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2072-2078.2001 · Cited by 73
Current Epidemiology of Multidrug-Resistant Gram-Negative Bacilli in the United States
Kallen, A. J., & Srinivasan, A. (2010) · Infection Control and Hospital Epidemiology · doi:10.1086/655996 · Cited by 70
Al‐Hasan, M. N., Eckel-Passow, J. E., & Baddour, L. M. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1424-6 · Cited by 61
Castanheira, M., Costello, S. E., Woosley, L. N., Deshpande, L. M., Davies, T. A., & Jones, R. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03930-14 · Cited by 59
Rennard, S. I., Thomashow, B. M., Crapo, J. D., Yawn, B. P., McIvor, A., Cerreta, S., Walsh, J. N., & Mannino, D. M. (2013) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2013.801309 · Cited by 59
Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections
Amin, A., Cerceo, E. A., Deitelzweig, S. B., Pile, J. C., Rosenberg, D. J., & Sherman, B. M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.04.018 · Cited by 56
Self-citationPogue, J. M., Mynatt, R. P., Marchaim, D., Zhao, J. J., Barr, V. O., Moshos, J. A., Sunkara, B., Chopra, T., Chidurala, S., & Kaye, K. S. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/674849 · Cited by 56
Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens
Grgurich, P. E., Hudcova, J., Lei, Y., Sarwar, A., & Craven, D. E. (2012) · Expert Review of Respiratory Medicine · doi:10.1586/ers.12.45 · Cited by 55
Skin and Soft Tissue Infections: The New Surgical Infection Society Guidelines
May, A. K. (2011) · Surgical Infections · doi:10.1089/sur.2011.034 · Cited by 54
Denys, G. A., Callister, S. M., & Dowzicky, M. J. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-24 · Cited by 52
Antimicrobial treatment for intra-abdominal infections
Mazuski, J. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.17.2933 · Cited by 51
The clinical impact of multidrug-resistant gram-negative bacilli in the management of septic shock
Pop-Vicas, A. E., & Opal, S. M. (2013) · Virulence · doi:10.4161/viru.26210 · Cited by 45
Chen, Z., Wu, J., Zhang, Y., Wei, J., Leng, X.-S., Bi, J., Li, R., Yan, L., Quan, Z., Chen, X., et al. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-217 · Cited by 45
Goldstein, E. J. C., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-12 · Cited by 45
Babinchak, T., Badal, R. E., Hoban, D. J., Hackel, M., Hawser, S., Lob, S. H., & Bouchillon, S. K. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.02.031 · Cited by 37
Shirah, G. R., & O’Neill, P. J. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.08.005 · Cited by 33
Vlieghe, E., Huang, T.-D., Phe, T., Bogaerts, P., Berhin, C., Smet, B. D., Peetermans, W. E., Jacobs, J. A., & Glupczynski, Y. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2350-9 · Cited by 33
Bloodstream Infections and Central Line–Associated Bloodstream Infections
Watson, C. M., & Al‐Hasan, M. N. (2014) · Surgical Clinics of North America · doi:10.1016/j.suc.2014.08.003 · Cited by 32
Towards Clinical Applications of Anti-endotoxin Antibodies; A Re-appraisal of the Disconnect
Hurley, J. C. (2013) · Toxins · doi:10.3390/toxins5122589 · Cited by 31
Resistant Gram-Negative Infections
Fraimow, H. S., & Nahra, R. (2013) · Critical Care Clinics · doi:10.1016/j.ccc.2013.06.010 · Cited by 22
Snydman, D. R. (2012) · Journal of Hospital Medicine · doi:10.1002/jhm.980 · Cited by 17
Klastersky, J. A., & Georgala, A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.06.002 · Cited by 16
Intra-abdominal and Pelvic Emergencies
Singh, S., & Khardori, N. M. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.09.002 · Cited by 14
Cited by
Motsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Morris, S., & Cerceo, E. (2020) · Antibiotics · doi:10.3390/antibiotics9040196 · Cited by 287
Self-citationAn Overview of the Recent Advances in Antimicrobial Resistance
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, Á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024) · Microorganisms · doi:10.3390/microorganisms12091920 · Cited by 285
Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana
Agyepong, N., Govinden, U., Owusu-Ofori, A., & Essack, S. Y. (2018) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-018-0324-2 · Cited by 142
Metadata
- Authors
- Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N.
- Venue
- Microbial Drug Resistance
- Publisher
- SAGE Publications
- Published
- 2016-07
- Volume
- 22
- Issue
- 5
- Pages
- 412-431
- ISSN
- 1076-6294 (ISSN-L)
- 1931-8448
- OpenAlex
- W2252374742
- Cited by
- 313
- References
- 129
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.